Enanta Pharmaceuticals Inc. (ENTA)
$14.02
$-0.07
(-0.50%)
As on 03-Sep-2026 16:00EDT
Market cap
$396 Mln
Revenue (TTM)
$65 Mln
P/E Ratio
--
P/B Ratio
4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
41.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
29,125,402
10 Years Aggregate
CFO
$35.11 Mln
EBITDA
$-54.45 Mln
Net Profit
$-99.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| -11.1 | 11.3 | 16.5 | 55.8 | -1.7 | -24.9 | -4.4 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| 174.3 | -38.6 | -79.8 | -37.8 | 77.6 | -31.9 | -12.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
|
14.0 | 396.1 | 65.3 | -63.2 | -109.4 | -55.5 | -- | 4.0 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment... of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Read more
-
President, CEO & Director
Dr. Jay R. Luly Ph.D.
-
President, CEO & Director
Dr. Jay R. Luly Ph.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Enanta Pharmaceuticals (ENTA)
What is the current share price of Enanta Pharmaceuticals Inc (ENTA) Today?
The share price of Enanta Pharmaceuticals Inc (ENTA) is $14.02 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Enanta Pharmaceuticals Inc (ENTA) has given a return of -1.66% in the last 3 years.
What is the current PB & PE ratio of Enanta Pharmaceuticals Inc (ENTA)?
Since, TTM earnings of Enanta Pharmaceuticals Inc (ENTA) is negative, P/E ratio is not available.
The P/B ratio of Enanta Pharmaceuticals Inc (ENTA) is 3.98 times as on 28-Aug-2026, a 23 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.13 |
3.95 |
2024 |
-1.89 |
1.70 |
2023 |
-1.76 |
1.09 |
2022 |
-8.78 |
3.33 |
2021 |
-14.54 |
2.88 |
What is the 52 Week High and Low of Enanta Pharmaceuticals Inc (ENTA)?
The 52-week high and low of Enanta Pharmaceuticals Inc (ENTA) are Rs 17.15 and Rs 7.05 as of 04-Sep-2026.
What is the market cap of Enanta Pharmaceuticals Inc (ENTA)?
Enanta Pharmaceuticals Inc (ENTA) has a market capitalisation of $ 396 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Enanta Pharmaceuticals Inc (ENTA)?
Before investing in Enanta Pharmaceuticals Inc (ENTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.